CN110891938B - 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 - Google Patents

四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 Download PDF

Info

Publication number
CN110891938B
CN110891938B CN201880033700.7A CN201880033700A CN110891938B CN 110891938 B CN110891938 B CN 110891938B CN 201880033700 A CN201880033700 A CN 201880033700A CN 110891938 B CN110891938 B CN 110891938B
Authority
CN
China
Prior art keywords
halogen
substituted
optionally substituted
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880033700.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110891938A (zh
Inventor
简·布朗
斯蒂芬·康诺利
斯特芬·V·F·汉森
加文·米尔恩
巴拉特·史姆普卡德
唐·史密斯
杰勒德·托马斯
特朗德·乌尔文
马贾兹·布瓦尔
阿龙·里格比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardan Treatment Co ltd
Original Assignee
Cardan Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardan Treatment Co ltd filed Critical Cardan Treatment Co ltd
Publication of CN110891938A publication Critical patent/CN110891938A/zh
Application granted granted Critical
Publication of CN110891938B publication Critical patent/CN110891938B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CN201880033700.7A 2017-03-24 2018-03-26 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂 Active CN110891938B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704714.3 2017-03-24
GBGB1704714.3A GB201704714D0 (en) 2017-03-24 2017-03-24 Pharmaceutical compounds
PCT/GB2018/000047 WO2018172727A1 (en) 2017-03-24 2018-03-26 Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators

Publications (2)

Publication Number Publication Date
CN110891938A CN110891938A (zh) 2020-03-17
CN110891938B true CN110891938B (zh) 2023-10-31

Family

ID=58687800

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880033700.7A Active CN110891938B (zh) 2017-03-24 2018-03-26 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂

Country Status (12)

Country Link
US (1) US11220483B2 (enExample)
EP (1) EP3601229B1 (enExample)
JP (1) JP7099672B2 (enExample)
KR (1) KR102636166B1 (enExample)
CN (1) CN110891938B (enExample)
AU (1) AU2018238102B2 (enExample)
BR (1) BR112019019868A2 (enExample)
CA (1) CA3057415A1 (enExample)
GB (1) GB201704714D0 (enExample)
MX (1) MX394818B (enExample)
WO (1) WO2018172727A1 (enExample)
ZA (1) ZA201906873B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用
JP7214053B2 (ja) * 2020-10-08 2023-01-27 イーライ リリー アンド カンパニー 糖尿病治療に有用な6-メトキシ-3,4-ジヒドロ-1h-イソキノリン化合物
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053446A2 (en) * 2006-11-02 2008-05-08 Piramal Life Sciences Limited Benzoxazepine compounds, their preparation and use
CN101663298A (zh) * 2007-02-22 2010-03-03 Irm责任有限公司 作为g蛋白偶联受体调节剂的噻唑衍生物
EP2298750A1 (en) * 2008-06-02 2011-03-23 Msd K.K. Novel isoxazole derivative
WO2016105118A2 (ko) * 2014-12-24 2016-06-30 주식회사 엘지생명과학 Gpr120 효능제로서의 바이아릴 유도체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005282721A1 (en) * 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ10阻害剤
CN101360743A (zh) 2006-01-30 2009-02-04 Irm责任有限公司 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物
WO2013019682A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053446A2 (en) * 2006-11-02 2008-05-08 Piramal Life Sciences Limited Benzoxazepine compounds, their preparation and use
CN101663298A (zh) * 2007-02-22 2010-03-03 Irm责任有限公司 作为g蛋白偶联受体调节剂的噻唑衍生物
EP2298750A1 (en) * 2008-06-02 2011-03-23 Msd K.K. Novel isoxazole derivative
WO2016105118A2 (ko) * 2014-12-24 2016-06-30 주식회사 엘지생명과학 Gpr120 효능제로서의 바이아릴 유도체

Also Published As

Publication number Publication date
RU2019133659A (ru) 2021-04-26
AU2018238102A2 (en) 2019-11-07
CA3057415A1 (en) 2018-09-27
GB201704714D0 (en) 2017-05-10
JP7099672B2 (ja) 2022-07-12
AU2018238102A1 (en) 2019-10-31
KR20190140936A (ko) 2019-12-20
US11220483B2 (en) 2022-01-11
EP3601229B1 (en) 2024-11-06
AU2018238102B2 (en) 2021-11-04
ZA201906873B (en) 2022-03-30
CN110891938A (zh) 2020-03-17
RU2019133659A3 (enExample) 2021-07-16
BR112019019868A2 (pt) 2020-04-22
KR102636166B1 (ko) 2024-02-13
WO2018172727A1 (en) 2018-09-27
EP3601229A1 (en) 2020-02-05
MX2019011314A (es) 2020-01-27
US20200317619A1 (en) 2020-10-08
MX394818B (es) 2025-03-24
JP2020515636A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
CN110891938B (zh) 四氢-苯并[d]氮杂环庚熳衍生物作为gpr120调节剂
JP6832342B2 (ja) 複素環化合物
JP4171700B2 (ja) 複素環化合物および使用方法
JP6163695B2 (ja) 新しいインダニルオキシフェニルシクロプロパンカルボン酸
KR20150118158A (ko) 항당뇨병 비시클릭 화합물
CN114258390A (zh) 用于疾病治疗的乙醇酸氧化酶抑制剂
WO2018006795A1 (zh) 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用
JP6441928B2 (ja) 新規インダニルオキシフェニルシクロプロパンカルボン酸
WO2016022448A1 (en) Antidiabetic bicyclic compounds
WO2016022742A1 (en) Antidiabetic bicyclic compounds
KR20190034318A (ko) Ido1억제제 및 이의 제조방법과 응용
JP2011513232A (ja) Gpr119活性のモジュレーターとしての化合物および組成物
CN115716827A (zh) 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
KR20220141331A (ko) P2x3 조정제
EA030561B1 (ru) Тетразолон-замещенные дигидропиридиноновые ингибиторы mgat2
TW202233591A (zh) 2-吡啶酮及其使用方法
TW202134248A (zh) Sstr5拮抗劑
US11905230B2 (en) Phenoxyacetic acid derivatives, preparation method thereof and use thereof as medicament
WO2010004198A2 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
RU2776801C2 (ru) Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120
KR20250004873A (ko) Atp 시트레이트 리아제의 마크로시클릭 억제제
JP2024515985A (ja) 6員芳香族ヘテロ尿素環の誘導体及びその使用
WO2022037617A1 (zh) 腈代三嗪类衍生物及其制备方法和应用
TW202233577A (zh) 羥吲哚及其使用方法
JP2000191663A (ja) 縮合ピリダジン誘導体の製造法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant